Key result
Azithromycin prescriptions after the 2012 FDA warning had modestly lower adjusted odds of being associated with a cardiac risk factor compared to before the warning (OR 0.938; 95% CI 0.936-0.940).
Why the study?
To measure the prevalence of cardiac risk factors among patients prescribed azithromycin before and after the 2012 FDA warning regarding fatal heart rhythms.
Does the 2012 FDA warning reduce the prescribing of azithromycin in patients with cardiac risk factors?
Cohort (n=12,971,078)
Does the 2012 FDA warning reduce the prescribing of azithromycin in patients with cardiac risk factors?
Despite the 2012 FDA warning, azithromycin continues to be frequently prescribed to patients with preexisting cardiac conditions or those taking QT-prolonging drugs.
Modest post-warning decline in cardiac-risk prescribing suggests limited impact; leaves open whether stronger interventions are needed.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2019) conducted a cohort in Patients prescribed azithromycin (n=12,971,078). Azithromycin prescription after the 2012 FDA warning vs. Azithromycin prescription before the 2012 FDA warning was evaluated on Presence of a cardiac risk factor (cardiac condition or concurrent use of QT-prolonging drugs) (OR 0.938, 95% CI 0.936-0.940). Azithromycin prescriptions after the 2012 FDA warning had modestly lower adjusted odds of being associated with a cardiac risk factor compared to before the warning (OR 0.938; 95% CI 0.936-0.940).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: